CV6 Therapeutics is building a pipeline of next-generation therapies designed to transform the effectiveness of cornerstone treatments in cancer and inflammatory diseases by altering their mechanism of action. Our lead clinical asset, CV6-168 -currently in Phase 1a trials – is engineered to work in combination with widely used cancer drugs like 5-FU, significantly enhancing therapeutic impact without adding toxicity.
Our preclinical program, targeting rheumatoid arthritis and related conditions, applies the same strategy: delivering safer, more effective therapies where current options often fall short.
Every CV6 assets is designed for smart, next-generation, combination use — seamlessly integrating with standard treatments to unlock greater efficacy and better outcomes for millions of patients.
